Only 14 digital-health companies out of more than 600 reviewed by GlobalSTL, the international company recruitment initiative of BioSTL, were invited to present to stakeholders and investors at the second annual GlobalSTL Health Innovation Summit on June 27 at Washington University in St. Louis.
Ten of those 14 companies are Israeli: CliniWorks (big data solution for monetizing clinical research and population health), Datos (big-data platform for leveraging patient-generated health data), MedAware (big-data solution for eliminating prescription errors), Medisafe (patient-engagement based medical adherence solution), Medorion (behavior-change platform using AI, behavioral science and digital marketing), Nym and Odoro (process/workflow automation), Profility (predictive analytics for point-of-care decision-making), TytoCare (fully remote clinical exam technology for telehealth) and VRHealth (a telehealth service providing virtual-reality based physical, rehab and cognitive therapy).
Dr. Gidi Stein, CEO and cofounder of MedAware, told ISRAEL21c: “We were proud to present our AI-driven technology for eliminating prescription-based medication errors at the summit last week. We had the opportunity to connect with forward-thinking healthcare organizations and were inspired by the robust healthcare ecosystem in St. Louis and the Midwest. We look forward to partnering with and bringing our lifesaving technology to these innovative institutions in the future.”
The highly curated event introduces transformational technologies to the St. Louis healthcare industry that can improve quality and access while lowering costs by solving challenges in patient care, health care delivery and hospital operations.
Each international company that applied to the summit was subjected to a thorough vetting process to identify the companies that had the best chance for getting a deal done. Last year’s inaugural summit directly resulted in five deals, including three for Israeli startups MDClone, Telesofia and Medial EarlySign.
“We specifically select companies that represent compelling, high-value technology for St. Louis’ health care systems and corporations, come with proven track records, and have the ability to immediately enter the U.S market,” Donn Rubin, president and CEO of BioSTL, said. “This approach has led to a total of 15 international companies with a new St. Louis location.”